Trastuzumab Deruxtecan for Breast Cancer
Trastuzumab Deruxtecan for Breast Cancer
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
In the DESTINY-Breast03 trial, Cortés et al. (Mar. 24 issue)
1
found that trastuzumab deruxtecan therapy prolonged progression-free survival to a greater extent than trastuzumab emtansine therapy among patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer previously treated with tras...
Alternative Titles
Full title
Trastuzumab Deruxtecan for Breast Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2676921864
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2676921864
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc2205309
